UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Incurable Platinum Refractory Germ Cell Tumors, Tumors
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832068
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
